Results 31 to 40 of about 44,703 (257)

MicroRNAs in melanoma development and resistance to target therapy [PDF]

, 2017
microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes.
Ascierto, Paolo Antonio, Ciliberto, Gennaro, Costantini, Susan, Croce, Carlo M, Fattore, Luigi, Malpicci, Debora, Mancini, Rita, Ruggiero, Ciro Francesco   +7 more
core   +1 more source

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China

Diagnostic Pathology, 2019
Background To determine the relevance of the single or combination mutations of BRAF V600E, TERT, and NRAS genes and the clinicopathologic relationship in papillary thyroid cancer (PTC).
Meiling Huang, Changjiao Yan, Jingjing Xiao, Ting Wang, Rui Ling   +4 more
doaj   +1 more source

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population

Plastic and Reconstructive Surgery, Global Open, 2022
Background:. The BRAF V600E mutation in the Thai population has been identified in a considerable percentage of people with cutaneous melanoma. The objectives of this study were to determine the prevalence of this mutation in cutaneous melanomas, conduct
Jiraroch Meevassana, MD, Kullawit Anothaisatapon, MD, Surawish Subbalekha, MD, Supitcha Kamolratanakul, MD, Tippawan Siritientong, RPh, PhD, Komkrit Ruangritchankul, MD, Pornthep Pungrasami, MD, Kevin J Hamill, PhD, Apichai Angsapatt, MD, Nakarin Kitkumthorn, DDS, PhD   +9 more
doaj   +1 more source

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab [PDF]

, 2015
Background: The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone.
Abouelkhair, KM, Cascinu, S, Del Prete, M, Faloppi, L, Giampieri, R, Ibrahim, EM, Loretelli, C, Mandolesi, A, Maristella, B, Scarpelli, M, Scartozzi, M   +10 more
core   +3 more sources

Utility of BRAF V600E Mutation-Specific Immunohistochemistry in DetectingBRAFV600E-Mutated Gastrointestinal Stromal Tumors [PDF]

American Journal of Clinical Pathology, 2015
As patients with BRAF V600E mutation respond to BRAF inhibitors, it is important to identify these mutations to stratify patients for the appropriate therapy. In this study, we evaluated the utility of a BRAF V600E allele-specific antibody in gastrointestinal stromal tumors (GISTs).BRAF V600E mutation-specific immunohistochemistry (negative, weak, or ...
Deepa T, Patil, Shuang, Ma, Mai, Konishi, Paula D, Carver, Marina, Pukay, Carol, Beadling, Christopher L, Corless, Brian P, Rubin   +7 more
openaire   +2 more sources

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. [PDF]

PLoS ONE, 2016
BACKGROUND:The BRAF V600E and telomerase reverse transcriptase (TERT) promoter mutations have been reported in papillary thyroid carcinoma (PTC). The aim of this retrospective cross-sectional study was to add further information regarding the prevalence ...
Jian Sun, Jing Zhang, Junliang Lu, Jie Gao, Xinyu Ren, Lianghong Teng, Huanli Duan, Yansong Lin, Xiaoyi Li, Bo Zhang, Zhiyong Liang   +10 more
doaj   +1 more source

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition

JCO Precision Oncology, 2020
PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with
Nobre L., Zapotocky M., Ramaswamy V., Ryall S., Bennett J., Alderete D., Guill J. B., Baroni L., Bartels U., Bavle A., Bornhorst M., Boue D. R., Canete A., Chintagumpala M., Coven S. L., Cruz O., Dahiya S., Dirks P., Dunkel I. J., Eisenstat D., Conter C. F., Finch E., Finlay J. L., Frappaz D., Garre M. L., Gauvain K., Bechensteen A. G., Hansford J. R., Harting I., Hauser P., Hazrati L. -N., Huang A., Injac S. G., Iurilli V., Karajannis M., Kaur G., Kyncl M., Krskova L., Laperriere N., Larouche V., Lassaletta A., Leary S., Lin F., Mascelli S., McKeown T., Milde T., la Madrid A. M., Morana G., Morse H., Mushtaq N., Osorio D. S., Packer R., Pavelka Z., Quiroga-Cantero E., Rutka J., Sabel M., Salgado D., Solano P., Sterba J., Su J., Sumerauer D., Taylor M. D., Toledano H., Tsang D. S., Fernandes M. V., van Landeghem F., van Tilburg C. M., Wilson B., Witt O., Zamecnik J., Bouffet E., Hawkins C., Tabori U.   +72 more
openaire   +7 more sources

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia

BMC Research Notes, 2022
Objective Thyroid cancer incidence has steadily increased in Indonesia. However, data on Kirsten rat sarcoma virus (KRAS) and EGFR mutations in thyroid cancer in Indonesia remain unavailable, except for BRAF-V600E, the most common BRAF gene mutation ...
Didik Setyo Heriyanto, Vincent Laiman, Nikko Vanda Limantara, Widyan Putra Anantawikrama, Fara Silvia Yuliani, Rita Cempaka, Sumadi Lukman Anwar   +6 more
doaj   +1 more source

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma [PDF]

Biochemical Pharmacology, 2011
The discovery of activating BRAF V600E mutations in 50% of all cutaneous melanomas has revolutionized the understanding of melanoma biology and provided new strategies for the therapeutic management of this deadly disease. Highly potent small molecule inhibitors of BRAF are now showing great promise as a novel therapeutic strategy for melanomas ...
Inna V, Fedorenko, Kim H T, Paraiso, Keiran S M, Smalley   +2 more
openaire   +2 more sources

DHODH modulates transcriptional elongation in the neural crest and melanoma [PDF]

, 2011
Melanoma is a tumour of transformed melanocytes, which are originally derived from the embryonic neural crest. It is unknown to what extent the programs that regulate neural crest development interact with mutations in the BRAF oncogene, which is the ...
AD Boiko, AL Rubinstein, AV Molofsky, BR Keegan, Charles Kaufman, Charles Y. Lin, Christopher J. Burke, CT Nguyen, D Mueller, Donna Neuberg, Erin Langdon, Frank Chen, GN Wheeler, Grant N. Wheeler, H Davies, Hannah K. Long, J Tsai, Jack Mosher, JE McLean, Jennifer Cech, K Krishnan, KT Flaherty, Leonard I. Zon, LM Graves, M Löffler, Martin Kramer, Matthew L. Tomlinson, MH Schiff, MJ Kaplan, PB Rahl, Peter B. Rahl, R Luo, Richard A. Young, Richard Mark White, RM Bakos, S Bixby, S Guo, SB Ng, Scott Granter, Sean Morrison, SK Hong, Sumon Datta, Sutheera Ratanasirintrawoot, T Aoki, T Wada, X Bai, Y Chen   +46 more
core   +1 more source